Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 10, 2015 1:30 PM ET


Company Overview of Creabilis SA

Company Overview

Creabilis SA, a clinical stage biotechnology company, engages in the research and development of new drugs for the treatment of dermatology and inflammatory diseases. Its development stage product portfolio includes CT327, a TrkA kinase inhibitor for the treatment of psoriasis and atopic dermatitis; CT340, a TrkA kinase and MAP2K3 kinase inhibitor for the treatment of inflammatory arthritis and pain; and CT637, an HMGB1 antagonist for the treatment of inflammatory conditions, such as lupus, acute liver failure, and fibrosis. The company is also involved in various early stage projects for the development of candidates for dermatological and other indications. Creabilis SA was founded in 2003...

5, Rue JeanMonnet

Luxembourg,  2180


Founded in 2003


352 26 420 522

Key Executives for Creabilis SA

Chief Operating Officer
Chief Business Officer
Chief Development Officer
Chief Scientific Officer
Compensation as of Fiscal Year 2015.

Creabilis SA Key Developments

Creabilis Appoints Catherine Moukheibir as Chairman of its Board of Directors

Creabilis Ltd. has appointed Catherine Moukheibir as Chairman of its Board of Directors. Catherine brings wide experience to Creabilis in aligning corporate goals with financial strategy, allowing companies to continue their strong growth trajectories from a position of financial strength. Catherine is currently a non-executive Board member of Ablynx and Zealand Pharma and a member of the management board of Innate Pharma. Catherine will lead Creabilis' Board at an exciting time for the company as it progresses its lead product CT327.

Creabilis Mulls IPO

Creabilis SA intends to go for initial public offering (IPO) later in 2014. Eliot Forster told the Sunday Telegraph he is eyeing a public listing for Creabilis. “We are exploring all options at the moment, but our ambition is to look hard at listing, if we can,” said Forster, adding that he would prefer to float the company in London rather than New York. He said the target fundraising will depend on the scale of trial required to satisfy US regulators.

Similar Private Companies By Industry

Company Name Region
Creabilis SA Europe

Recent Private Companies Transactions

Private Placement
December 31, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Creabilis SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at